发明授权
US08981082B2 Process for preparing an intermediate of the macrocyclic protease inhibitor TMC 435
有权
制备大环蛋白酶抑制剂TMC 435中间体的方法
- 专利标题： Process for preparing an intermediate of the macrocyclic protease inhibitor TMC 435
- 专利标题（中）： 制备大环蛋白酶抑制剂TMC 435中间体的方法
-
申请号： US14350138申请日： 2012-10-26
-
公开(公告)号： US08981082B2公开(公告)日： 2015-03-17
- 发明人: Andras Horvath , Stijn Wuyts , Dominique Paul Michel Depré , Wouter Louis J. Couck , Jozef Ludo Jan Cuypers , Syuzanna Harutyunyan , Gregory Fabien Sebastian Binot
- 申请人： Janssen Pharmaceuticals, Inc.
- 申请人地址： US NJ Titusville
- 专利权人： Janssen Pharmaceuticals, Inc.
- 当前专利权人： Janssen Pharmaceuticals, Inc.
- 当前专利权人地址： US NJ Titusville
- 代理商 Andrea Jo Kamage
- 优先权： EP11187025 20111028
- 国际申请： PCT/IB2012/055900 WO 20121026
- 国际公布： WO2013/061285 WO 20130502
- 主分类号： C07D417/14
- IPC分类号： C07D417/14 ; C07D417/04
摘要：
The present invention relates to an improved process for preparing (2R,3aR,10Z,11aS,2aR,14aR)-cyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxylic acid, 2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydro-2-[[7-methoxy-8-methyl-2-[4-10(1-methylethyl)-2-thiazolyl]-4-quinolinyl]oxy]-5-methyl-4,14-dioxo-, ethyl ester. This compound is an intermediate in the overall synthesis route of the macrocyclic compound TMC 435. TMC 435 is an inhibitor of NS3/4A protease which plays an important role in the replication of the hepatitis C virus.
公开/授权文献
信息查询
